BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23732486)

  • 1. [Vascular endothelial growth factor in malignant and non malignant prostatic tissue: Association with tumor recurrence at one year after prostatectomy].
    Acuña P; Ellwanger A; Ramírez A; Cardemil F; Vega J; Casalino R; Madrid E
    Rev Med Chil; 2013 Feb; 141(2):153-9. PubMed ID: 23732486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
    Jackson MW; Bentel JM; Tilley WD
    J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
    Gyftopoulos K; Vourda K; Sakellaropoulos G; Perimenis P; Athanasopoulos A; Papadaki E
    Urol Int; 2011; 87(4):464-9. PubMed ID: 21912077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
    Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
    Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
    Wang Q; Diao X; Sun J; Chen Z
    Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.
    Thomas GV; Schrage MI; Rosenfelt L; Kim JH; Salur G; deKernion JB; Dorey F; Said J; Reiter RE
    J Urol; 2000 Dec; 164(6):1987-91. PubMed ID: 11061897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
    Urologiia; 2004; (1):17-21. PubMed ID: 15022438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
    Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
    Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
    Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
    Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
    Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of vascular endothelial growth factor (VEGF) in prostate disease.
    Walsh K; Sriprasad S; Hopster D; Codd J; Mulvin D
    Prostate Cancer Prostatic Dis; 2002; 5(2):119-22. PubMed ID: 12497000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study.
    Yao JL; Ryan CK; Francis CW; Kohli M; Taubman MB; Khorana AA
    Cancer Invest; 2009 May; 27(4):430-4. PubMed ID: 19219655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
    Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ
    In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.